Epstein Secrets

nspiracy to possess with intent to distribute meth and to possession with intent to distribute meth. U.S. District Judge Susan P. Wafters presided. Schuster was allowed to self surrender." Prosecutors "said an investigation into meth trafficking led to Schuster and a co-defendant, Byrne Martin Mestas. Me

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

onspiracy to possess with intent to distribute meth and to possession with intent to distribute meth. U.S. District Judge Susan P. Watters presided. Schuster was allowed to self surrender." Prosecutors "said an investigation into meth trafficking led to Schuster and a co-defendant, Byrne Martin Mestas. Me

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

nspiracy to possess with intent to distribute meth and to possession with intent to distribute meth. U.S. District Judge Susan P. Watters presided. Schuster was allowed to self surrender." Prosecutors "said an investigation into meth trafficking led to Schuster and a co-defendant, Byrne Martin Mestas. Me

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug